Evidence map›Paper›PMID 29312294›Full record

ReviewFrontiers in immunology2017

Chronicles of Cell Death Foretold: Specificities in the Mechanism of Disposal.

Lindsey D Hughes, Lidia Bosurgi, Sourav Ghosh, Carla V Rothlin

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Lifting the innate immune barriers to antitumor immunity.Journal for immunotherapy of cancer · 2020
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lindsey D HughesDepartment of Immunobiology, School of Medicine, Yale University, New Haven, CT, United States.
Lidia BosurgiI. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Sourav GhoshDepartment of Pharmacology, School of Medicine, Yale University, New Haven, CT, United States.
Carla V RothlinDepartment of Immunobiology, School of Medicine, Yale University, New Haven, CT, United States.

Funding

INTERDISCIPLINARY IMMUNOLOGY TRAINING PROGRAMT32AI007019 · NIAID · YALE UNIVERSITY · PI Carrie L. Lucas, David G. Schatz · 1985 to 2026
$14.4M
TAM receptor tyrosine kinases in inflammatory boweldiseaseR01AI089824 · NIAID · YALE UNIVERSITY · PI ROTHLIN, CARLA · 2010 to 2018
$3.9M
An innate immune checkpoint in cancer immunotherapy.R01CA212376 · NCI · YALE UNIVERSITY · PI GHOSH, SOURAV, ROTHLIN, CARLA · 2017 to 2021
$3.1M
NCI NIH HHS R01 CA212376NIAID NIH HHS R01 AI089824NIAID NIH HHS T32 AI007019
6 · The paper itself

Abstract

Massive turnover of cells occurs through apoptosis during the constant remodeling of our tissues at homeostasis, from the shedding of cells at exposed barrier surfaces to the elimination of autoreactive lymphocytes. However, a surge of apoptotic cells also accompanies tissue damage, infection, and inflammation. A salient feature of apoptosis in either scenario is the exposure of phosphatidylserine (PtdSer) on the outer leaflet of the plasma membrane. In response to this cue, a range of phagocytes are charged with the sizeable task of engulfing apoptotic bodies and disposing of the billions of cells that perish each day. The presence of apoptotic cells in the remarkably distinct immunological settings described above, therefore, raises the question of how phagocytes are able to coordinate appropriate responses to apoptotic cells-from their silent removal to the production of growth factors or tissue repair molecules-following such a ubiquitous signal as PtdSer exposure. Here, we consider several emergent properties of phagocytes and apoptotic cell clearance that may facilitate specification among this suite of potential responses.

Indexed as

apoptosishomeostasisphagocytic receptorssignal integrationtissue repair

Identifiers

PMID29312294
PMCPMC5732325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.